Navigation Links
Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
Date:10/14/2010

HOBOKEN, N.J., Oct. 14 /PRNewswire/ -- Octapharma USA is accepting applications for the Octapharma 25th Anniversary Grants Program, which supports clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immune therapy, intensive care and emergency medicine. The application deadline is April 1, 2011.

Octapharma AG, one of the largest human protein products manufacturers in the world, launched the Octapharma Grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA.

Earlier this year, the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center in Chicago was awarded the first grant in the Octapharma program to support research into blood induced joint damage in hemophilia.

Grant applications are accepted online only at www.octapharmagrants.com.  All grant requests will be evaluated by the Octapharma Grants Committee and grant recipients will be announced shortly afterward. Please visit www.octapharmagrants.com for a complete description of the grants program, including the application and review process.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (Human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
2. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
3. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
4. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
6. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
7. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
8. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
9. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
10. Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
11. Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... 26, 2017 , ... New patients with missing teeth in Fitchburg, ... a referral. Dr. Cotey is a trusted dentist who has placed many dental implants ... Patients with missing teeth in Fitchburg, WI, are encouraged to find out if they ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro X ... the timeline and write in the lyrics to any song. ProLyric flies in the text ... of the text can be added modularly for optimal control. ProLyric makes editing any music ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
(Date:6/25/2017)... ... ... With a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many ... is easy with laser hair removal. , The process of summer waxing and constantly ... all you want to do is get out, dive in and cool off. There is ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... offering genetic testing for medications in select Florida and Texas doctors' offices and ... , This new application of genetic testing recognizes the role genes play in ...
Breaking Medicine News(10 mins):